Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes

BACKGROUND: PD-L1 has been used as a biomarker to select patients for treatment of PD-1/PD-L1 inhibitors. MATERIALS AND METHODS: In this study, we assessed the clinicopathological features of breast cancers that are associated with PD-L1 expression, as well as its relationship with other immune comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Yunbi, Tsang, Julia Y, Shao, Yan, Poon, Ivan K, Tam, Fiona, Shea, Ka-Ho, Tse, Gary M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982370/
https://www.ncbi.nlm.nih.gov/pubmed/35380716
http://dx.doi.org/10.1093/oncolo/oyab063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982370/
https://www.ncbi.nlm.nih.gov/pubmed/35380716
http://dx.doi.org/10.1093/oncolo/oyab063

Ejemplares similares